A.Mina Tran

12966 Euclid Street, Suite 310
Garden Grove, California 92840
(714) 427-002 Fax. (714) 427-0025
www.tranlawgroupus

OTC Markets Group, Inc.
304 Hudson Street
2nd Floor
New York, New York 10013

Re: Optec International, Inc. (OPTI)

Annual Information and Disclosure Statement and Financial Statements for the Years Ended June 30, 2019, as published by OTC Markets Group, Inc. on March 16, 2020, through May 22, 2019, and 10-K for the period June 30, 2018, 10-Q for the period September 30, 2018 and 10-Q for the period of 12-31-2018, as published by SEC, respectively.

Dear Sir or Madam:

The following constitutes an opinion letter regarding Optec International, Inc., ("Issuer" or "Company") Public disclosures within meaning and scope of Rule 144(c)(2) of the Securities Act of 1933 and OTC Markets Group, Inc.'s Pink Guidelines. No person other than OTC Markets Group, Inc. ("OTC") may rely upon this opinion in their determination of OPTI's compliance obligations of public disclosure under the Act, however, OTC may publish this opinion through the OTC Disclosure & News Service for viewing by the public and regulators.

Specifically, the Issuer prepared and posted with the Securities and Exchange Commission the following. On October 15, 2018 posted, the **Annual Report for the year ending June 30, 2018,** on November 14, 2018 posted, the Quarterly report for September 30, 2018, on February 14, 2019 posted, the Quarterly report for December 31, 2018.

Specifically, the issuer prepared and posted the following with OTC Markets Group, Inc. (OTC).

Date	Title	Period End Date
5-22-2019	Quarterly Report-OTC Markets Quarterly Disclosure Statement	3-31-2019
5-22-2019	Quarterly Report OPTI Financial statement for Quarter Ending March 31, 2019	3-31-2019
5-30-2019	AMENDED, Quarterly Report-OTC Markets Quarterly Disclosure Statement	3-31-2019

2-18-2020	Quarterly Report, Income Statement	9-30-2019
2-18-2020	Quarterly Report, Income Statement	12-31-2019
3-16-2020	**Annual Report, OTC Markets Annual Disclosure Statement and Annual Financial Statements**	**6-30-2019**
3-16-2029	Quarterly Report, OTC Markets, Disclosure Statement and Quarterly Financial Statements	9-30-2019
3-18-2020	AMENDED, Quarterly Report, OTC Markets, Disclosure Statement and Quarterly Financial Statements	9-30-2019
3-16-2020	Quarterly Report, OTC Markets, Disclosure Statement and Quarterly Financial Statements	12-31-2019
3-18-2020	AMENDED, Quarterly Report, OTC Markets, Disclosure Statement and Quarterly Financial Statements	12-31-2019
4-9-2020	Annual Report-Amendment III PE June 30, 2019 Disclosure Statement	6-30-2019
4-9-2020	Quarterly Report-Amendment III PE September 30, 2019	9-30-2019
4-9-2020	Quarterly Report-Amendment III PE December 31, 2019	12-31-2019

This "Letter" is provided to OTC with respect to adequate current information in regard to the securities issued by the Issuer (the "Securities"). I have acted as legal counsel to Issuer in connection with review of the posting of the information on the OTC News Service (www.otcmarkets.com).

1. OTC is entitled to rely on this letter in determining whether the Issuer has made current information publicly available within the meaning of Rule 144(c)(2) of the Securities Act of 1933, as amended (the "Act").

2. The undersigned is a United States resident and has been retained by Issuer for the purpose of rendering this Letter. The undersigned's relationship with the Issuer is limited to the conduct of a due diligence inquiry and review of the statements and representations that the Issuer has made on OTC Markets Group, Inc. and the preparation and submission of this letter to you. The undersigned is not and has been an employee nor an officer or director of the Issuer, and I do not own any stock currently, nor do I have any agreement to acquire such in the future, directly or beneficially or for payment for services.

3. I have made such legal and factual examinations and inquiries as I have deemed advisable or necessary for the purpose of rendering this Letter. In addition, I have examined, among other things, originals or copies of such corporate records and documents of Issuer, certificates of public officials, and such other documents and questions of law that I considered necessary, advisable, or appropriate for the purpose of rendering this letter. As

to matters of fact, I have made such inquiries of the Issuer's officers as I deemed necessary to render this opinion, and I believe that such sources were reliable.

4. The undersigned is a member of the Bar of the State of California. I express no opinion as to the laws of any jurisdiction other than corporate laws of the State of California; laws of the State of Wyoming only where specifically referenced or where there is an issue related to conducting business in the State of Wyoming; and the federal laws of the United States of America. I express no opinion with respect to the effect or application of any other laws. Special rulings of authorities administering any of such laws of opinions of other counsel have not been sought or obtained by me in connection with rendering this letter. I am not relying upon the work of any other law firm or legal counsel in connection with the due diligence inquiry and review of the statements, and representations of the Issuer and the preparation of this letter.

5. Counsel is not currently, or has in the past five years, been the subject of an investigation, hearing, or proceeding by the SEC, the U.S. Commodity Futures Trading Commission (CFTC), the Financial Industry Regulatory Authority (FINRA), or any other federal, state, or foreign regulatory agency.

6. Counsel is a United States citizen and is permitted to practice before the Securities and Exchange Commission and has not been prohibited from practice there under. Counsel is not currently, or has been in the past five years, suspended or barred from practicing in any state or jurisdiction. Counsel has not been charged in a civil or criminal case.

7. In conducting my examination in connection with the delivery of this Letter, as to matters of fact I have relied upon information obtained from public officials, officers of the Issuer, and other sources, I confirm that I believed all such sources to be reliable. I further assumed without investigation or confirmation (i) the genuineness of all signatures on original documents; (ii) the authenticity and completeness of all documents submitted to use as originals; (iii) the conformity to original documents of all documents submitted to me as copies; (iv) the legal capacity of all natural persons executing any documents; (v) the due authorization, execution, and delivery of all documents on all parties other than Issuer; and, (vi) the truth, accuracy and completeness of the Information, factual matters, representations, and warranties contained in the information I received from public officials, officers of Issuer, and other sources.

8. The following documents have been reviewed by the undersigned in connection with the delivery of this Letter (the "Information"). The applicable date for this letter is deemed to be April 10, 2020. Except in instances of confidentiality or for items and issues of a proprietary nature, the information reviewed is publicly available through the OTC News Service with the date each respective document was posted on the OTC News Service noted below. This list does not include documents that are the subject of letters covering

prior periods. Additional documents reviewed by the undersigned that may or may not be publicly available through the OTC News Services are listed as well. The information referenced includes as follows and such other information and documents that I considered necessary under the specific circumstances to render this opinion.

FILINGS AND DISCLOSURE
OTC DISCLOSURE & NEWS

PUBLISH DATE	TITLE	PERIOD END DATE
4-9-2020	Quarterly Report-Amendment III PE December 31, 2019	12-31-2029
4-9-2020	Quarterly Report-Amendment III PE September 30, 2019	9-30-2019
4-9-2020	Annual Report-Amendment III PE June 30, 2019 Disclosure Statement	6-30-2019
3-18-2020	Quarterly Report- Amended Quarterly Report PE	12-31-2019
3-18-2020	Quarterly Report - Amended Quarterly Report PE	9-30-2019
3-16-2020	Quarterly Report - Quarterly Report Period Ending	12-31-2019
3-16-2020	Quarterly Report - Quarterly Report	9-30-2019
3-16-2020	Annual Report - June 30 2019 Annual Report	6-30-2019
2-18-2020	Quarterly Report - Income Statement	12-31-2019
2-18-2020	Quarterly Report - Income Statement	9-30-2019
5-30-2019	Quarterly Report-OTC Markets Quarterly Disclosure Statement Pursuant to the Pink Disclosure Guidelines AMENDED	3-31-2019
5-22-2019	Quarterly Report - OPTEC International Quarterly financial Statements For the Quarter Ending March 31, 2019	3-31-2019
5-22-2019	Quarterly Report- OTC Markets Quarterly Disclosure Statement Pursuant to the Pink Disclosure Guidelines	3-31-2019
5-14-2019	Quarterly Report - OPTEC International Quarterly financial Statements For the Quarter Ending March 31, 2019	3-31-2019
5-14-2019	Quarterly Report - OTC Markets Quarterly Disclosure Statement Pursuant to the Pink Disclosure Guidelines	3-31-2019
10-15-2018	Annual Report - Annual Report 10-K	6-30-2018
9-25-2018	OTCQB- Optec International, Inc. OTCBQB Certification	6-30-2018
9-21-2018	OTCQB- Optec International, Inc. OTCBQB Certification	6-30-2018

After considering the information presented to me, it is my opinion that said documents are accurate, up-to-date and contain the most current information available regarding Optec International, Inc., all as published on the OTC Markets Group website.

9. To my knowledge, the Information as of the date covered by Issuer's various disclosure and filings: (i) constitutes "adequate current public information" concerning the Securities and the Issuer and "is available" within the meaning of Rule 144 (c)(2) under the Securities Act; (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"),(iii) complies as to form with the

OTC Market Group's OTC Pink Sheet Disclosure Guidelines which are on the Internet at www.otcmarkets.com; and (iv) has been posted through the OTC Disclosure and News Service.

10. The Issuer's Financial Statement for the period ending 6-30-2018, which are audited were prepared by Pritchett, Silver & Hardy, P.C. of Salt Lake City, Utah. Certification was provided by Peter Sollenne, Principal Executive Officer on October 12, 2018.

    The Issuer's Financial Statements, (from the published date) May 14, 2019 to the present which are not audited, were prepared by or under the supervision of Roger Pawson the company's Chief Executive Officer, Chief Financial Officer and Director, he is familiar with all aspects of Optec International, Inc. at the periods stated in the filings.

11. The issuers transfer agent is Worldwide Stock Transfer, LLC, and is registered with the SEC as confirmed by checking the SEC's EDGAR system. The contact information for the transfer agent is:

    Worldwide Stock Transfer, LLC
    1 University Plaza Dr, #505
    Hackensack, NJ 07601
    Telephone 201-820-2008
    Email: info@wwstr.com.

    The method used to confirm the number of outstanding shares of common stock set forth in the information Statement was to contact a member of management and receive written confirmation as to the number of outstanding shares by West Coast Stock Transfer.

12. The undersigned hereby confirms that the undersigned has undertaken the following in connection with the delivery of this Letter: I have met telephonically with all of management, consisting of Roger Pawson, Chief Executive Officer, Secretary, an Director of the Company, and each director, consisting solely of Roger Pawson; (ii) reviewed the Information, published by the Issuer on the OTC News Service; (iii) discussed the above-internal equity matter; and (iv) also discussed what I considered to be pertinent Information, with a majority of management and a majority of the directors of the Issuer.

    The following is a list, and provides pertinent information for each respective person, of each (i) executive officer, directors, general partner, and other control person of the Issuer; and, (ii) promoter, finder, consultant, or any other advisor of the Issuer that assisted, prepared, or provided information with respect to the Issuer's disclosure or who received securities as consideration for services rendered to the Issuer:

    Roger Pawson, CEO, Principal Financial Officer and Director, 5858 Dryden Place, Carlsbad, California 92008, www.optecintl.com, 760-444-5566, The business address for all officers and directors is: 5858 Dryden Place, Carlsbad, California 92008, www.optecintl.com, 760-444-5566

The Company is not a reporting issuer pursuant to the Securities Exchange Act of 1934 (the "Exchange Act") and, therefore, does not file periodic reports with the SEC.

13. To the best of my knowledge, after inquiry of management and the directors, neither the Issuer, any 5% shareholder, nor counsel is under investigation by any federal or state regulatory authority for any violation of federal or state securities laws, and if so, the details of such investigation must be provided in such letter.

14. No person or entity other than OTC Markets Group, Inc. is entitled to rely upon this opinion. OCT Markets Group, Inc. however, is granted full and complete permission and rights to publish this document via the OTC Disclosure and News Service for viewing by the general public and regulators. The public and OTC Markets Group, Inc. may rely on the above in determining whether the Issuer has made adequate current information publicly available within the meaning of Rule 144(c)(2)) of the Securities Act at 1933. The information which has been posted via OTC Disclosure News Service constitutes adequate current public information, is available within the meaning of Security and Exchange Commission Rule 144(c)(2) of the Securities Act, and includes all the information that a broker-dealer would be required to obtain from an issuer in order to publish a quotation for its securities pursuant to Rule 15c211under the Securities Exchange Act of 1934, and complies as to form with the OTC Market Groups Guidelines for Providing Adequate Current information.

15. Based on my review of filings, and information supplied to me by management of the Issuer, the Issuer, nor any of it's predecessors, is or ever was a "shell company" as defined in Rule 405 of the Securities Act of 1933 and 12b-2 of the Exchange Act of 1934. I have been informed, and my research has confirmed that there has never been a period of time when there was not material activity, and the Issuer is not considered a shell.

On behalf of the Issuer, I appreciate your assistance. Please feel free to contact the undersigned should you have any comments or questions in regard to the information or any of the matters addressed herein.

Very Truly Yours,

Mina Tran

A. Mina Tran